Incidence of Hospitalized Tachyarrhythmia in Patients with Type 2 Diabetes Mellitus Using Tirzepatide or Other Long-Acting Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: A Descriptive Analysis

In this analysis, we described the incidence of hospitalized tachyarrhythmia among patients with type 2 diabetes mellitus who newly initiated tirzepatide (Mounjaro) or other long-acting glucagon-like peptide-1 (GLP-1) receptor agonists, by product and patient characteristics including race/ethnicity groups in the Sentinel Distributed Database. This analysis contains three reports:

• Report 1: Contains results from the primary analysis, using a 365-day lookback period for enrollment, inclusion/exclusion criteria, and most covariates. Patients were excluded if an event occurred on the index date.
• Report 2: Contains results from the first sensitivity analysis, which used a shorter 183-day lookback period for enrollment and covariate assessment.
• Report 3: Contains results from the second sensitivity analysis, in which events were allowed to occur on the index date, removing the blackout period restriction. 

The study period includes data from May 13, 2022 to June 30, 2023. We distributed this request to seven Sentinel Data Partners on September 28, 2023.